主页 > 医药生命 >
【Cancer research】有前景的抗肿瘤化合物
New approaches in cancer therapy that facilitate selective targeting of cancers have been emerging in recent years. Apoptin represents a new anti-cancer tool in such new approaches with great potentials. Two routes can be taken using Apoptin or its encoding cDNA, i.e. as protein therapy or gene therapy.
A research article published on 21 June 2008, in the World Journal of Gastroenterology refers. The research team led by Prof. Duan from Life Sciences Institute of Northwest University used molecular biology,to generated a cDNA construct of SP-Tat-Apoptin fusion. Cancer cells transfected with this construct would express the recombinant Apoptin and apoptosis would be induced in them. By incorporating a synthetic signal peptide authors also expected Apoptin to be secreted outside of the transfected cells as Tat-Apoptin fusion protein and re-enter adjacent untransfected HepG2 cells, enabling the construct to act as both protein and gene therapeutic agent and increasing the potency of Apoptin in cancer therapy.
Having a synthetic signal peptide, the recombinant Apoptin was able to be secreted outside of the transfected cells and re-enter adjacent untransfected HepG2 cells. The recombinant protein was detected in the cytoplasm in HepG2 and HUVEC cells shortly after co-culture of the cells with the cell-free supernatant of the transfected CHO cell culture, indicating the secreted Tat-Apoptin fusion protein contained in the CHO cell culture media was able to enter these cells. The fusion protein was later found in the nucleus in HepG2 cells and induced HepG2 cell apoptosis.
The new secretory characteristic increased the possibility of Apoptin being used in cancer gene therapy. However, there are still a large number of unanswered questions regarding the mechanisms and therapeutic usage of Apoptin, and further studies are certainly required.
There are more HCC cell line used to confirm the results in our study, for example, Bel-7402 HCC cell line. The result about Bel-7402 will be discussed in future. Meanwhile in HUVEC cells, SP-Tat-Apoptin remained in the cytoplasm and no induction of apoptosis above the background level was observed. 本人认领该文编译，若超过48小时未能交稿，请他人自由认领。 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领 A Promising Anti-Cancer Compound
一种有前景的抗肿瘤化合物。
New approaches in cancer therapy that facilitate selective targeting of cancers have been emerging in recent years. Apoptin represents a new anti-cancer tool in such new approaches with great potentials. Two routes can be taken using Apoptin or its encoding cDNA, i.e. as protein therapy or gene therapy.
近年促进选择性作用于肿瘤靶区的新方法已经出现。Apoptin在这类新途径中呈现出巨大的抗肿瘤潜力。有两种途径可以运用Apoptin或它所编码的cDNA，如蛋白疗法或基因疗法。
A research article published on 21 June 2008, in the World Journal of Gastroenterology refers. The research team led by Prof. Duan from Life Sciences Institute of Northwest University used molecular biology,to generated a cDNA construct of SP-Tat-Apoptin fusion. 这在一篇新发表在2008年6月21日世界胃肠杂志上的研究文章谈及。研究团队由来自西北大学生命科学研究所的Duan博士领导，运用分子生物学技术来产出SP-Tat-Apoptin 融合重建的cDNA。Cancer cells transfected with this construct would express the recombinant Apoptin and apoptosis would be induced in them.经过该合成物转染的肿瘤细胞将表达Apooptin的重组体，这样凋亡机制就在它们中得到诱导。 By incorporating a synthetic signal peptide authors also expected Apoptin to be secreted outside of the transfected cells as Tat-Apoptin fusion protein and re-enter adjacent untransfected HepG2 cells, enabling the construct to act as both protein and gene therapeutic agent and increasing the potency of Apoptin in cancer therapy. 通过结合人造的信号肽，研究者也希望Apooptin能做为Tat-Apoptin融合蛋白分泌到转染细胞外，并重进入边缘未转染HepG2细胞，使得该合成物能扮演蛋白和基因治疗的角色，从而增加Apoptin做为肿瘤治疗的潜力。
Having a synthetic signal peptide, the recombinant Apoptin was able to be secreted outside of the transfected cells and re-enter adjacent untransfected HepG2 cells. 有了人工信号肽，重组Apoptin 能够被分泌到转染细胞外并重进入边缘未转染HepG2 cell。The recombinant protein was detected in the cytoplasm in HepG2 and HUVEC cells shortly after co-culture of the cells with the cell-free supernatant of the transfected CHO cell culture,该细胞在无细胞悬液的转染CHO细胞联合培养基中，在HepG2 和HUVEC细胞中检测到重组蛋白，indicating the secreted Tat-Apoptin fusion protein contained in the CHO cell culture media was able to enter these cells. 这表明这些存在于CHO细胞培养基中的Tat-Apoptin 融合蛋白能进入这些细胞。The fusion protein was later found in the nucleus in HepG2 cells and induced HepG2 cell apoptosis. 该融合蛋白随后在HepG2细胞核中找到，并诱导了该细胞的凋亡。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-01 05:11
医学,生命科学网